RESUMEN
Aim: To achieve, at least, 95% clearance of loads of treated infections so that pathogens do not develop resistance against drugs used for treatment. Materials and Methodology: Lower doses of Aluminum-magnesium silicate (AMS)-stabilized antimicrobials (Piparazine, Ampicillin, Chloroquine and Sulphadimidine), supported with immune stimulants, were used to treat respective sensitive and resistant infections. Results: Recommended doses of Piparazine, Ampicillin and Chloroquine cleared only 82.94%, 80.68% and 20% of Helignosomoides bakeri, Salmonella gallinarum and Plasmodium berghei infections, respectively. Lower doses (75%) of the AMS-stabilized Piparazine and Ampicillin cleared 96.82% and 97.84% of the treated infections. Supporting the lower doses of AMS-stabilized Chloroquine and AMS-stabilized Ampicillin with immune stimulants led to 100% clearance of P. berghei infection and 95.80% clearance of Ampicillin-resistant Escherichia coli infection, respectively. Conclusion: Prolonging bioavailability of drugs with AMS, minimizing side effects of drugs by using their lower doses for treatment, and enhancing immune responses of treated patients, help treatments to prevent and cure resistant infections.